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CASE REPORT
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Abstract
Anaplastic large T-cell lymphoma (ALCL) is frequently associated with the t(2;5)(p23;q35). Here, we report a case of ALCL
with an atypical translocation of t(2;5)(p24;q13) and other complex translocations. This complex abnormal karyotype may
result in chemotherapy resistance and a poor outcome. Interestingly, a hypophyseal tumor was detected simultaneously by
magnetic resonance imaging in this case. We think it is probable that the tumor in the hypophysis might be associated with the
ALCL.
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A case report
A 19-year-old woman was admitted to our hospital
with a 15-day history of lymphadenopathy and fever.
Physical examination showed lymphadenophathy
and splenomegaly. Hemogram showed hemoglobin
(Hb) 93 g/L, white blood cell (WBC) 39  10
9/L,
platelets 273  10
9/L, with differential count of lym-
phocytes 44%, monocytes 8%, eosinophils 2%, neu-
trophilic granulocytes 40%, and immature cells 6%.
The WBC counts rose to 122  10
9/L, and the platelet
counts dropped to 16  10
9/L in one week. Bone-
marrow aspiration and biopsy revealed hypercellular,
predominant myeloid cells showing a full range of
maturation. Karyotypic analysis showed: 46, X,-X,
t(2;5)(p24;q13), der(7)(q22), del(17)(q12), -18,
+1-2mar[3]/46, XX, der(2), t(2;5)(p24;q13), -5, del
(17)(q12), -18, +1-2mar[1]/47, idem, +8[1]/46, XY,
normal karyotype[5] (Figure 1). Computed tomogra-
phy (CT) scan of the abdomen and chest showed
splenomegaly and lymphadenophathy. She underwent
an excisional biopsy of an enlarged inguinal lymph
node. The architecture of the lymph node was
distorted by cellular proliferation, but sinusoids were
still present. The cellular proliferation included small
lymphoid cells and large lymphoid cells with round
nuclei, admixed with some spindle cells. On immu-
nostaining,thelargecellswerenegativeforCD2,CD3,
CD5, and CD7, but were positive for CD43. They
were CD30+ and ALK+ (nuclear cytoplasmic pat-
tern). A diagnosis of primary systemic anaplastic
large-cell lymphoma, ALK+, T-cell-type was made.
Analysis of cells from bone-marrow by ﬂow cytometry
conﬁrmed the presence of abnormal T-cells. The
patient was initially treated with one cycle of VDCP
(cyclophosphamide 750 mg/m
2 on days 1 and 8, lipo-
somal doxorubicin 8 mg/m
2 on days 1 through 3,
vincristine 1.4 mg/m
2 on days 1 and 8, and prednisone
1 mg/kg/d on days 1 through 14 and 0.5 mg/kg/d on
days 15 through 21), after which the enlarged lymph
nodes disappeared. But the percentage of lymphocytes
was still high, and the patient had fever every day. The
repeated analysis by ﬂow cytometry still showed the
existence of abnormal T-cells. Another cycle of CHOP
(cyclophosphamide 750 mg/m
2 on day 1, vincristine
1.4 mg/m
2 on day 1, doxorubicin 50 mg/m
2 on day 1,
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DOI: 10.3109/03009734.2010.500061and prednisone 100 mg/d on days 1 through 5) was
given followed by VP16 (etoposide) plus cytarabine
(Ara-C). She began to feel fatigue one week later even
though red blood cells were infused several times.
Levels of thyroid hormones, including total triiodothy-
ronine (TT3), total thyroxine (TT4), thyrotropic-
stimulating hormone (TSH), free triiodothyronine
(FT3), and free thyroxine (FT4), were very low.
Enhanced magnetic resonance imaging (MRI) of the
brain indicated a tumor in the hypophysis. Euthyrox
was given, and then she felt much better. Repeated
analysis by ﬂow cytometry showed the remarkable
decrease of abnormal T-cells. Unfortunately, the
patient ﬁnally died due to pneumonia one week later.
Anaplastic large T-cell lymphoma (ALCL) was ﬁrst
recognized in 1985 by Stein et al. who reported
consistent expression of Ki-1 antigen (later desig-
nated CD30) with frequent cohesive proliferation of
large pleomorphic cells. Two distinct clinical forms of
primary ALCL are now recognized: limited to the skin
and systemic. It is frequently associated with the t(2;5)
(p23;q35), resulting in expression of a fusion gene
nucleophosmin-anaplastic lymphoma kinase (NPM-
ALK). Variant translocations other than t(2;5) occur
in up to 15%–20% of the cases: these include t(1;2)
(q21;p23) (chimeric protein TPM3-ALK); inv(2)
(p23;q35) (ATIC-ALK); t(2;3)(p23;q21) (TRK-fused
gene(TFG)-ALK);t(2;19)(p23;q13.1)(tropomyosin4
(TPM4)-ALK); t(2;X)(p23;q11-12) (moesin (MSN)-
ALK), and a clathrin, heavy chain-like 1 (CLTCL)-
ALK fusion transcript typically resulting from a t(2;17)
(p23;q23) (1,2). Our patient had atypical translocation
of t(2;5)(p24;q13), which has different break points in
chromosomes compared with typical t(2;5)(p23;q35).
This has not been reported in the literature. The trans-
location also has association with a receptor tyrosine
(ALK) gene since the patient was ALK+ by immuno-
staining. We do not know which type of ALK fusion
genethistranslocationgenerated.Butitissurethatthe
translocation caused activated tyrosine kinase that is
oncogenic. Though most investigators consider that
ALCL generally behaves as a usually intermediate to
high-grade lymphoma, still, comparative studies in
diffuse large-cell lymphomas have shown an associa-
tion between ALK expression and a favorable out-
come (3). In a series that included 57 patients with
T-cell/null ALCL, the 5-year overall survival rate was
93% in patients who were ALK+ compared with 37%
for those who were ALK- (4). However, in multivar-
iate analysis, only high international prognosis index
(IPI) and CD56 positivity were independent predic-
tors of poor outcome. In an Italian series, ALK+
patients with intermediate or high IPI score had a
5-year overall survival (OS) rate of only 41% (5). It
has been reported that the prognosis of patients with
variant translocation is similar to that of patients with
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Figure 1. Karyotype: 46, X,-X, t(2;5)(p24;q13), der(7)(q22), -13,del(17)(q12), -18, +mar1, +mar2.
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atypical t(2;5) and many other complex transloca-
tions, these translocations may also be the predictor
of poor outcome.
The majority of ALK+ ALCL cases present as
advanced stage (III or IV) systemic disease with gen-
eralized lymphadenopathy and extranodal involve-
ment, particularly of the skin and soft tissues, with
involvement of the gut and nervous system (CNS)
being a rare event (4). Bone-marrow involvement has
been initially considered as a rare event in ALCL.
When immunohistochemistry with anti-CD30 and
anti-epithelial membrane antigen (EMA) was used
to study bone-marrow samples, malignant cells could
be detected in as many as 43% of cases (7). In the
bone-marrow, higher WBC counts and lower platelet
counts suggested bone-marrow involvement. But we
did not ﬁnd any malignant cells in the bone-marrow.
A leukemoid reaction may explain the leukocytosis but
cannot explain the decreased platelet count. The anal-
ysis by ﬂow cytometry or immunohistochemistry
might help to ﬁnd abnormal cells and distinguish
the leukemoid reaction from bone-marrow involve-
ment. Our patient later complained of fatigue, and
enhanced MRI of the brain indicated a hypophyseal
tumor. To our knowledge, there are no other reports
about ALCL involving the hypophysis. Since the
patient did not feel any discomfort before the
presence of lymphadenopathy, and she felt obvious
fatigue due to low levels of thyroid hormones during
therapy, we think it is probable that the tumor in the
hypophysis might be associated with ALCL.
The corner-stone of most treatment protocols con-
sists of alkylating agents, anthracyclines, vinca alka-
loids, and corticosteroids. The US standard has
generally been to treat ALCL with CHOP chemo-
therapy (8). In the literature, it has been reported that
the leukemia-like protocol Italian Association of Pedi-
atric Hematology and Oncology (AIEOP)-92 was
found to be an effective treatment for childhood
ALCL (9). Our patient had a high percentage of
abnormal T-cells in the bone-marrow. We therefore
treated her with a leukemia-like protocol (VDCP
regimen). The patient responded well at ﬁrst since
the enlarged lymph nodes disappeared. But the
abnormal T-cells in the bone-marrow remained,
which indicated that these cells might be resistant
to VDCP chemotherapy. VP16 and Ara-C may
have some effect, but bone-marrow suppression was
severe. So, further observations are needed to ﬁnd the
best therapeutic regime for this kind of ALCL.
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Figure 2. Biopsy of an enlarged inguinal lymph-node. Immunostaining showed the large cells were positive for ALK-1 (400).
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